About AvenCell
AvenCell is a Healthcare company based in Watertown (United States) founded in 2021. Next-generation switchable CAR T-cell immunotherapies are developed for cancer treatment. AvenCell has raised $362 million across 4 funding rounds from investors including Blackstone, Intellia Therapeutics and Piper Sandler. The company has 105 employees. Its chief executive, as recorded, is Andrew Schiermeier. AvenCell offers products and services including Universal Switchable CAR and Allogeneic Platform. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is AvenCell Therapeutics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
AvenCell was founded in 2021 in Watertown, United States, within the biotechnology sector focused on immunotherapy. Allogeneic platforms are developed to address limitations in current T-cell therapies. Switchable CAR-T mechanisms are utilized, incorporating universal effector cells and soluble adaptors for precise antigen targeting. Controllability of reactivity is enhanced to reduce side effects, thereby improving safety and the therapeutic window for oncology applications.
- Headquarters Watertown, United States
- Employees 105
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website avencell.com
- Social LinkedIn
- Legal Name Avencell Therapeutics, Inc.
- Total Equity Funding$362M (USD)
in 4 rounds
- Latest Funding Round$40M (USD), Grant
Jul 2025
- InvestorsBlackstone
& 9 more
- Employee Count105
Products & Services of AvenCell
AvenCell offers a comprehensive portfolio of products and services, including Universal Switchable CAR and Allogeneic Platform.
Enables controllable CAR-T reactivity for targeted cancer treatment.
Facilitates safe and effective allogeneic T-cell therapies for cancers.
Funding Insights of AvenCell
AvenCell has successfully raised a total of $362M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $40 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $362M
- Total Rounds 4
- Last Round Grant — $40M
- First Round $250M
(Jun 2021)
- Investors Count 10
All 4 funding rounds of AvenCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $40M | Grant | – | – | |
| Oct 2024 | $112M | Series B | – | Novo Holdings | |
| Feb 2023 | $284,143 | Grant | – | – | |
| Jun 2021 | $250M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in AvenCell
AvenCell has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Intellia Therapeutics and Piper Sandler.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
| nybcventures.com | ||||
Advisory services for corporate mergers and acquisitions are provided. | 1895 | pipersandler.com | Minneapolis, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Therapeutics using CRISPR/Cas9 are developed for various diseases. | 2014 | intelliatx.com | Cambridge, United States | |
| amed.go.jp | ||||
Cellex is established as a full-service CDMO for cell and gene therapy. | cellex.me | Cologne, Germany |
Investor details for AvenCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AvenCell
2 people are tracked at AvenCell (2 in leadership); the tracked headcount is 105.
| Name | Role | Group |
|---|---|---|
Manfred Klevesath | Managing Director | Leadership |
Andrew Schiermeier | CEO | Leadership |
Complete people profiles for AvenCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AvenCell
3 dated milestones of AvenCell across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AvenCell is founded.
- Funding First funding round of $250.0M.
- Funding Latest funding round, Grant, of $40.0M.
Competitors of AvenCell
AvenCell has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of AvenCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AvenCell
The website of AvenCell (avencell.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 27.3% vs previous month
Websites whose visitors overlap most with AvenCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nextrnatx.com | 100% | 1.8K | #8,619,826 | View details | |
| landmarkbio.com | 99% | 1.9K | #8,466,954 | View details | |
| werewolftx.com | 97% | 4.5K | #3,895,284 | View details | |
| cuebiopharma.com | 96% | 4.9K | #7,063,180 | View details | |
| fluentbio.com | 95% | 4.7K | #3,913,179 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for AvenCell
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as AvenCell (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avencell
Complete news archive for AvenCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AvenCell
AvenCell was founded in 2021.
AvenCell is headquartered in Watertown, United States.
Andrew Schiermeier is the CEO of AvenCell, as recorded in our data.
AvenCell is a funded company, having raised a total of $362M across 4 funding rounds to date. The company's 1st funding round was a Series A of $250M, raised on Jun 2021.
AvenCell has 105 employees.
AvenCell was founded in 2021 in Watertown, United States, within the biotechnology sector focused on immunotherapy. Allogeneic platforms are developed to address limitations in current T-cell therapies. Switchable CAR-T mechanisms are utilized, incorporating universal effector cells and soluble adaptors for precise antigen targeting. Controllability of reactivity is enhanced to reduce side effects, thereby improving safety and the therapeutic window for oncology applications.
AvenCell offers Universal Switchable CAR and Allogeneic Platform.
AvenCell has 10 investors. Key investors include Blackstone, Intellia Therapeutics, Piper Sandler, European Union, and Eight Roads Ventures.
AvenCell operates through Avencell Therapeutics, Inc..